Health economic evaluation alongside the Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial (E-PROSPECT): a cost-effectiveness analysis
Authors:
- 26 October 2022
- journal article
- research article
- Published by Springer Nature in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
- Vol. 69 (12) , 1515-1526
Abstract
Purpose We sought to compare the cost-effectiveness of probiotics and usual care with usual care without probiotics in mechanically ventilated, intensive care unit patients alongside the Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial (PROSPECT). Methods We conducted a health economic evaluation alongside the PROSPECT randomized control trial (October 2013–March 2019). We adopted a public healthcare payer’s perspective. Forty-four intensive care units in three countries (Canada/USA/Saudi Arabia) with adult critically ill, mechanically ventilated patients (N = 2,650) were included. Interventions were probiotics (Lactobacillus rhamnosus GG) vs placebo administered enterally twice daily. We collected healthcare resource use and estimated unit costs in 2019 United States dollars (USD) over a time horizon from randomization to hospital discharge/death. We calculated incremental cost-effectiveness ratios (ICERs) comparing probiotics vs usual care. The primary outcome was incremental cost per ventilator-associated pneumonia (VAP) event averted; secondary outcomes were costs per Clostridioides difficile-associated diarrhea (CDAD), antibiotic-associated diarrhea (AAD), and mortality averted. Uncertainty was investigated using nonparametric bootstrapping and sensitivity analyses. Results Mean (standard deviation [SD]) cost per patient was USD 66,914 (91,098) for patients randomized to probiotics, with a median [interquartile range (IQR)] of USD 42,947 [22,239 to 76,205]. By comparison, for those not receiving probiotics, mean (SD) cost per patient was USD 62,701 (78,676) (median [IQR], USD 41,102 [23,170 to 75,140]; incremental cost, USD 4,213; 95% confidence interval [CI], −2,269 to 10,708). Incremental cost-effectiveness ratios for VAP or AAD events averted, probiotics were dominated by usual care (more expensive, with similar effectiveness). The ICERs were USD 1,473,400 per CDAD event averted (95% CI, undefined) and USD 396,764 per death averted (95% CI, undefined). Cost-effectiveness acceptability curves reveal that probiotics were not cost-effective across wide ranges of plausible willingness-to-pay thresholds. Sensitivity analyses did not change the conclusions. Conclusions Probiotics for VAP prevention among critically ill patients were not cost-effective. Study registration data www.ClinicalTrials.gov (NCT01782755); registered 4 February 2013.Keywords
Funding Information
- Canadian Institutes of Health Research
- McMaster University
- St. Joseph’s Healthcare Hamilton
- Canadian Frailty Network
- Physicians' Services Incorporated Foundation
- Hamilton Academic Health Sciences Organization
- Academic Medical Organization of Southwestern Ontario
This publication has 44 references indexed in Scilit:
- CONSOLIDATED HEALTH ECONOMIC EVALUATION REPORTING STANDARDS (CHEERS) STATEMENTInternational Journal of Technology Assessment in Health Care, 2013
- Is primary prevention of Clostridium difficile infection possible with specific probiotics?International Journal of Infectious Diseases, 2012
- Microbial Translocation Across the GI TractAnnual Review of Immunology, 2012
- A Meta-Analysis of Probiotic Efficacy for Gastrointestinal DiseasesPLOS ONE, 2012
- Induction of Treg cells in the mouse colonic mucosa: A central mechanism to maintain host–microbiota homeostasisSeminars in Immunology, 2012
- Probiotics for preventing acute upper respiratory tract infections2011
- Dalteparin versus Unfractionated Heparin in Critically Ill PatientsNew England Journal of Medicine, 2011
- Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: PreventionJournal of Critical Care, 2008
- Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated PneumoniaAmerican Journal of Respiratory and Critical Care Medicine, 2005
- Economics notes: Opportunity costBMJ, 1999